Pharmacological treatment patterns in heart failure: a population-based cohort study. : Eur J Clin Pharmacol

Archive ouverte

Bosco-Levy, Pauline | Favary, C. | Jove, J. | Lassalle, R. | Moore, Nicholas | Droz-Perroteau, C.

Edité par CCSD ; Springer Verlag -

International audience. BackgroundAlthough the efficacy and safety of existing therapies of heart failure (HF) have been demonstrated in clinical trials, little is known about the treatment patterns in clinical practice, especially in France.ObjectivesTo describe the treatment initiation patterns and the subsequent treatment changes among HF patients, in the first year following an incident hospitalization for HF, in a French real-world setting.MethodsA cohort of patients aged ≥ 40 years, with an incident hospitalization for HF between 01/01/2008 and 31/12/2013, was identified in the 1/97th permanent random sample of the French nationwide claims database and followed 1 year. HF drug exposure—beta blockers (BB), angiotensin-converting enzyme inhibitors (ACEI), angiotensin receptor blockers (ARBs), aldosterone antagonists (AA), diuretics, digoxin, or ivabradine—was assessed quarterly using a Proportion of Days Covered ≥ 66% (≥ 60 days out of the 90 days of the quarter), by considering HF drugs individually or in combination. Drug changes were assessed between each quarter.ResultsBetween 2008 and 2013, 7387 patients were included. Their mean age was 77.7 years (± 12.0 years) and 51.6% were women. During the follow-up, 24.4% died, 20% were not exposed to any HF treatment, 48.3 to 43.2% had diuretics, one third had BB or ACEI, 9% had ARB or AA, 6% had digoxin, and 2% had ivabradine. The main change occurred between the first and the second quarter for 53.1% of the initially untreated patients.ConclusionThis study provides valuable information on treatment patterns after an initial hospitalization for HF.

Consulter en ligne

Suggestions

Du même auteur

Effectiveness of Cetuximab as First-Line Therapy for Patients With Wild-Type KRAS and Unresectable Metastatic Colorectal Cancer in Real-Life Practice: Results of the EREBUS Cohort. : Clin Colorectal Cancer

Archive ouverte | Rouyer, M. | CCSD

International audience. INTRODUCTION: Few real-life data are available on cetuximab benefit. The EREBUS cohort was performed to assess metastases resection rate, use, safety, and survival outcomes in wild-type KRAS ...

Benefit-risk profile of dabigatran compared with vitamin-K antagonists in elderly patients with non-valvular atrial fibrillation: results from a cohort study in the French nationwide claims database. : European Heart Journal

Archive ouverte | Cottin, Y. | CCSD

International audience

Effectiveness and safety of standard and reduced doses of dabigatran versus rivaroxaban in non-valvular atrial fibrillation: A cohort study in the snds french nationwide claims database. : Value in Health

Archive ouverte | Blin, P. | CCSD

International audience

Chargement des enrichissements...